• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma

by | Jun 21, 2023 | Uncategorized

Source: Cure Today articles Post Content Read More

The latest myeloma treatment advances from ASCO 2023

by | Jun 20, 2023 | Uncategorized

Source: Cure Today articles Post Content Read More

FDA places clinical hold on trial of CAR-T for advanced myeloma after patient death

by | Jun 20, 2023 | Uncategorized

The FDA placed a clinical hold on a clinical program designed to investigate a chimeric antigen receptor T-cell therapy for treatment of relapsed or refractory multiple myeloma following a patient death.The hold applies to IMMagine-1, a multicenter phase 2 trial...

Maintenance Darzalex Regimen Promising in Post-Transplant Myeloma

by | Jun 10, 2023 | Uncategorized

Source: Cure Today articles Maintenance Darzalex, with or without Pomalyst was safe and efficacious in treating patients with relapsed myeloma who underwent salvage autologous hematopoietic stem cell transplant. Read More

Cilta-cel CAR-T provides ‘unprecedented’ benefit for advanced multiple myeloma

by | Jun 6, 2023 | Uncategorized

CHICAGO — Ciltacabtagene autoleucel significantly extended PFS compared with standard therapy for adults with relapsed and lenalidomide-refractory multiple myeloma, results from the randomized phase 3 CARTITUDE-4 study showed.A single dose of the chimeric antigen...

Elranatamab Elicits Responses in Pretreated Relapsed/Refractory Myeloma

by | Jun 4, 2023 | Uncategorized

Source: Cure Today articles Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy. Read More
« Older Entries
Next Entries »

Recent Content

  • FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria
  • Daffodils and Determination from a Patient with Chronic Lymphocytic Leukemia
  • Real-World Data Show Improved Survival With Sacituzumab Govitecan as First-Line ADC in HER2-Low Breast Cancer
  • Alternative Methods in Identifying Allergic, Nonallergic Type 2 Asthma Endotypes Are Necessary
  • First Patient Dosed in a Phase 1/2 Trial for Small Cell Lung Cancer
  • Lepodisiran Reduces Lipoprotein(a) By Nearly 94% in Adults With Elevated Levels of Lp(a)
  • First Patient with Colon Cancer Dosed in a Phase 2 Study of TCMCB07
  • Advances in the Management of HR+/HER2- Ultralow and -Low Metastatic Breast Cancer: New Horizons and Treatment Frontiers
  • April 2025 Pharmacy Policy Updates
  • Radiation Delay in NSCLC May Aid Outcomes, But Raises Toxicity Risks
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT